Skip to main content
FinSpry Logo
FinSpry
AKBA logo
AKBA
(NASDAQ)
Akebia Therapeutics, Inc.
$1.38-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Akebia Therapeutics (AKBA) Stock Price & Financial Analysis

Akebia Therapeutics Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$1.36 - $1.40
52-Week High$4.08
52-Week Low$1.14
Open$1.39
Volume1.88M
Average Volume (3M)1.88M
Market Cap366.21M
Shares Outstanding265.37M
Price to Sales (P/S)1.58
Price to Book (P/B)11.47
EV/EBITDA18.67
Revenue (TTM)236.19M
Net Income (TTM)-5.34M
Free Cash Flow (TTM)67.61M
EPS (TTM)$-0.02
Profit Margin-2.26%
Operating Margin9.95%
Return on Equity (ROE)-16.39%
Debt to Equity6.63
50-Day MA$1.36
200-Day MA$2.34
52-Week Change-26.18%
Annual Dividend$0.00
Dividend Yield0.00%

Frequently Asked Questions About Akebia Therapeutics

What is the current stock price for AKBA?

As of the latest trading session, AKBA stock trades at $1.38. The 52-week range is $1.14–$4.08, with a day range of $1.35–$1.40.

What is the P/E ratio for AKBA?

The P/E ratio (Price-to-Earnings) for AKBA is shown in the Key Statistics section. This valuation metric helps compare Akebia Therapeutics, Inc. to industry peers.

Does AKBA pay dividends?

Akebia Therapeutics does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for AKBA?

Based on 3 analysts, the consensus for AKBA is Buy. The average 12-month price target is $NaN, representing a NaN% downside from the current price.

What is the market cap of AKBA?

Akebia Therapeutics's market capitalization is $366.2M, classifying it as a small-cap company. Akebia Therapeutics operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.